v3.25.4
Collaborations (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
AbbVie's receivable from Janssen $ 12,589 $ 10,919  
AbbVie's payable to Janssen $ 34,734 31,945  
Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Share of collaboration development costs responsible by the entity (as a percent) 40.00%    
Janssen Biotech, Inc | Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen (as a percent) 60.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 101 162 $ 228
AbbVie's receivable from Janssen 218 237  
AbbVie's payable to Janssen 189 282  
Janssen Biotech, Inc | Collaborative arrangement | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 954 1,140 1,245
Janssen Biotech, Inc | Collaborative arrangement | International      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
International - AbbVie's share of profits (included in net revenues) 821 899 931
Genentech, Inc. | Collaborative arrangement      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 1,064 990 869
AbbVie's share of development costs (included in R&D) 63 84 109
Genentech, Inc. | Collaborative arrangement | United States      
Collaborative Arrangements and Non-collaborative Arrangement Transactions      
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 28 $ 29 $ 41